Table 1.
Demographic and clinical characteristics of enrolled patients
| Patients, n | % | |
|---|---|---|
| Sex | ||
| Female/male | 56/86 | 39/61 |
| Comorbidities | ||
| Cardiovascular | 34 | 24 |
| COPD asthma | 7 | 5 |
| Coronary heart disease | 8 | 6 |
| Diabetes mellitus | 20 | 14 |
| Autoimmune disorders | 6 | 4 |
| HCV | 6 | 4 |
| HBV | 6 | 4 |
| Influenza vaccine | ||
| Yes/no | 89/53 | 63/37 |
| Previous COVID-19 disease | ||
| Yes/no | 9/133 | 6/94 |
| Type of tumor | ||
| Lung cancer | 58 | 41 |
| Breast cancer | 25 | 18 |
| Melanoma | 17 | 12 |
| Kidney cancer | 10 | 7 |
| Head and neck cancer | 6 | 4 |
| Gastrointestinal cancer | 20 | 14 |
| Others | 6 | 4 |
| Type of oncological treatment | ||
| ICIs + chemotherapy | 18 | 12,7 |
| ICIs | 63 | 44,4 |
| Chemotherapy | 61 | 42,9 |
| Number of days between the second dose of vaccine and the booster | ||
| Before 5 months | 45 | 31,7 |
| After 5 months | 97 | 68,3 |
COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; HBV, hepatitis B virus; HCV, hepatitis C virus; ICIs, immune checkpoint inhibitors.